Find the latest Regulatory and Legislative Optometry news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.
June 29, 2026
1 min read
Save
FDA approves Lumvoa for thyroid eye disease
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics.
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid
New Drug Approved for Thyroid Eye Disease
Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease,…
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion…
Find the latest Primary Care Optometry news articles, videos, podcasts, and meeting coverage from medical experts and key opinion…
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient…
Find the latest Regulatory and Legislative Ophthalmology news articles, videos, podcasts, and meeting coverage from medical…
